BACKGROUND/AIM: Chemotherapy for intraocular retinoblastoma is used to shrink individual retinal tumours to a size amenable to focal treatments. Quantitative data regarding retinal tumour response following treatment with primary systemic carboplatin are reported. METHODS: Changes in area and largest basal diameter of tumours that were exposed to carboplatin, had no concomitant focal treatment, and had digital funduscopic photography performed before and after treatment, were measured. Response was evaluated. RESULTS: 36 tumours were measured following one treatment: 34/36 (94.4%) responded, with a 37.1% mean decrease in area (median = 37.0%; range 4.0%-76.7%). Mean reduction in basal diameter was 21.3% (med = 21.0%; -7.9%-52.5%). 20 tumours were treated with a second cycle: 15/20 (75.0%) responded. Mean decrease in area was 17.8% (med = 15.3%; -7.0%-49.7%). The mean cumulative decrease in area after two treatments was 55.1% (med = 56.2%; 33.0%-74.5%). Mean cumulative reduction in basal diameter was 33.6% (med = 33.6%; 10.9%-53.2%). 12 tumours were treated with a third cycle: 3/12 (25.0%) responded, 8/12 were stable, and one progressed. Mean decrease in area was 5.4% (med = 7.2%; -17.7%-20.6%). Cumulative decrease in area after three treatments was 58.1% (med = 57.3%; 34.8%-77.2%). Mean cumulative reduction in basal diameter was 38.8% (med = 38.2%; 19.1%-54.1%). CONCLUSIONS: Carboplatin caused measurable shrinkage of retinoblastoma tumours. Response was greatest following the initial treatment and decreased with subsequent treatments.
BACKGROUND/AIM: Chemotherapy for intraocular retinoblastoma is used to shrink individual retinal tumours to a size amenable to focal treatments. Quantitative data regarding retinal tumour response following treatment with primary systemic carboplatin are reported. METHODS: Changes in area and largest basal diameter of tumours that were exposed to carboplatin, had no concomitant focal treatment, and had digital funduscopic photography performed before and after treatment, were measured. Response was evaluated. RESULTS: 36 tumours were measured following one treatment: 34/36 (94.4%) responded, with a 37.1% mean decrease in area (median = 37.0%; range 4.0%-76.7%). Mean reduction in basal diameter was 21.3% (med = 21.0%; -7.9%-52.5%). 20 tumours were treated with a second cycle: 15/20 (75.0%) responded. Mean decrease in area was 17.8% (med = 15.3%; -7.0%-49.7%). The mean cumulative decrease in area after two treatments was 55.1% (med = 56.2%; 33.0%-74.5%). Mean cumulative reduction in basal diameter was 33.6% (med = 33.6%; 10.9%-53.2%). 12 tumours were treated with a third cycle: 3/12 (25.0%) responded, 8/12 were stable, and one progressed. Mean decrease in area was 5.4% (med = 7.2%; -17.7%-20.6%). Cumulative decrease in area after three treatments was 58.1% (med = 57.3%; 34.8%-77.2%). Mean cumulative reduction in basal diameter was 38.8% (med = 38.2%; 19.1%-54.1%). CONCLUSIONS:Carboplatin caused measurable shrinkage of retinoblastoma tumours. Response was greatest following the initial treatment and decreased with subsequent treatments.
Authors: D L Friedman; B Himelstein; C L Shields; J A Shields; M Needle; D Miller; G R Bunin; A T Meadows Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: A L Murphree; J G Villablanca; W F Deegan; J K Sato; M Malogolowkin; A Fisher; R Parker; E Reed; C J Gomer Journal: Arch Ophthalmol Date: 1996-11
Authors: M A Smith; L Rubinstein; J R Anderson; D Arthur; P J Catalano; B Freidlin; R Heyn; A Khayat; M Krailo; V J Land; J Miser; J Shuster; D Vena Journal: J Clin Oncol Date: 1999-02 Impact factor: 44.544
Authors: C L Shields; J A Shields; M Needle; P de Potter; S Kheterpal; A Hamada; A T Meadows Journal: Ophthalmology Date: 1997-12 Impact factor: 12.079
Authors: H S Chan; G DeBoer; J J Thiessen; A Budning; J E Kingston; J M O'Brien; G Koren; E Giesbrecht; G Haddad; Z Verjee; J L Hungerford; V Ling; B L Gallie Journal: Clin Cancer Res Date: 1996-09 Impact factor: 12.531
Authors: Debra L Friedman; Mark Krailo; Doojduen Villaluna; Dan Gombos; Bryan Langholz; Rima Jubran; Carol Shields; Linn Murphree; Joan O'Brien; Sandra Kessel; Carlos Rodriguez-Galindo; Murali Chintagumpala; Anna T Meadows Journal: Pediatr Blood Cancer Date: 2016-12-26 Impact factor: 3.167
Authors: L Lumbroso-Le Rouic; I Aerts; D Hajage; C Lévy-Gabriel; A Savignoni; N Algret; N Cassoux; A-I Bertozzi; M Esteve; F Doz; L Desjardins Journal: Eye (Lond) Date: 2015-10-02 Impact factor: 3.775
Authors: Qiuling Liu; Yafeng Wang; Han Wang; Yingying Liu; Tao Liu; Patricia Elena Kunda Journal: J Cancer Res Clin Oncol Date: 2013-05-21 Impact factor: 4.553
Authors: Jasmine H Francis; Y Pierre Gobin; Ira J Dunkel; Brian P Marr; Scott E Brodie; Gowtham Jonna; David H Abramson Journal: PLoS One Date: 2013-08-21 Impact factor: 3.240